IL-6, IL-1β, and MDA Correlate with Thrombolysis in Myocardial Infarction (TIMI) Risk Score in Patients with Acute Coronary Syndrome | Bentham Science
Generic placeholder image

Recent Advances in Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-2708
ISSN (Online): 2772-2716

Research Article

IL-6, IL-1β, and MDA Correlate with Thrombolysis in Myocardial Infarction (TIMI) Risk Score in Patients with Acute Coronary Syndrome

Author(s): Marcus V. de Paula da Silva, Pedro Henrique Villar-Delfino, José A. Nogueira-Machado and Caroline M.O. Volpe*

Volume 15, Issue 2, 2021

Published on: 25 February, 2022

Page: [71 - 79] Pages: 9

DOI: 10.2174/2772270816666220211091231

Price: $65

Open Access Journals Promotions 2
Abstract

Background: Inflammation plays a significant role in the pathophysiology of Acute Coronary Syndrome (ACS) but is not included in current risk stratification.

Objective: This study aimed at determining the association between Thrombolysis in Myocardial Infarction (TIMI) risk score and inflammatory biomarkers in the ACS, including unstable angina (UA), Non-ST Segment Elevation Myocardial Infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). We hypothesized that inflammatory biomarkers could add prognostic value to the TIMI risk score.

Methods: In this cross-sectional study, serum levels of interleukins (IL)-6 and IL-1β and MDA (malondialdehyde) were quantified by ELISA and colorimetry, respectively, of patients with ACS (n = 48; 31.3 % with UA, 33.3 % with NSTEMI, and 35.4 % with STEMI) and healthy controls (n = 43). We assessed the TIMI scores in the first 24 h after symptom onset.

Results: The results showed that patients with ACS had significantly higher levels (p<0.05) of the inflammatory biomarkers IL-6, IL-1β, and MDA than the control group. However, we found no significant differences in IL-6, IL-1β, and MDA levels among the patients with ACS according to their classification as UA, NSTEMI, and STEMI. Positive correlations were observed between TIMI and IL-6 (r=0.68), IL-1β (r= 0.53), and MDA (r=0.58) in patients with UA and between TIMI and IL-1β (r= 0.62) in STEMI patients.

Conclusion: These data suggested the presence of a pro-inflammatory profile in patients with ACS as well as positive correlations between TIMI scores and the inflammatory biomarkers IL-6, IL-1β, and MDA in patients with UA and between TIMI scores and IL-1β in patients with STEMI. Combining inflammatory biomarkers with the TIMI risk score could provide better insight into the processes involved in ACS.

Keywords: Acute coronary syndrome, TIMI, IL-6, IL-1β, MDA, inflammation.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy